While the coronavirus has impacted millions of Americans across the United States, it has hit the elderly population particularly hard. In fact, more than 40 percent of coronavirus deaths in the U.S. have been linked to long-term care facilities, according to a New York Times survey. In an effort to bring those numbers down, pharmaceutical company Eli Lilly, in partnership with the National Institutes of Health (NIH), has just launched a late-stage antibody treatment trial focusing on residents and staff at nursing homes.
"COVID-19 has had a devastating impact on nursing home residents," Lilly's chief scientific officer Daniel Skovronsky said in a statement. "We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals."
The trial is expected to enroll up to 2,400 participants who live or work at a facility and have recently been diagnosed with the disease. The trial will evaluate the safety and success of using LY-CoV555, a potent, neutralizing antibody that works against the spike protein of the novel coronavirus. The trial will look at whether a single dose of the antibody treatment reduces the rate of infection over four weeks as well as symptoms over eight weeks.
"The importance of these kinds of therapies for people like the elderly or immunocompromised is that they can provide the hope and the safety net that these people really need right now," said Andrew Adams, vice president of new therapeutic modalities & COVID-19 research at Eli Lilly, who is overseeing the trial. "I think people in those populations are really desperate and looking for something to help with the coronavirus."
Eli Lilly is taking its trial on the road with customized mobile research units that can travel directly to areas that are experiencing outbreaks.
"This is an interesting solution, to bring the medicine to these vulnerable patients," said Adams. "This lets us be flexible and move these trials around the country, tracking these trials as we come across them."
Adams said he is hoping Eli Lilly will have results on the efficacy of these antibodies in the fourth quarter of this year. Even if successful, though, he says research for a vaccine needs to continue.
"These have to be thought of as more of a bridge, where a vaccine provides long-term protection in terms of years of immunity, where we will provide hopefully in the range of months with these types of treatments. We hope this to be a short-term bridge to the long-term effective vaccination," he said.
Tensions from the Russia-Ukraine war have spilled into space. The head of Russia's space agency has threatened to pull the country out of the International Space Station if sanctions aren't lifted on the country — but that doesn't seem to be happening any time soon. What would it mean if Russia really did leave the ISS, who would it harm the most, and what would the consequences be both for the other ISS partners, and private space travel? Casey Dreier, Chief Advocate & Senior Space Policy Adviser at The Planetary Society, joins Closing Bell to discuss.
Almost every industry now uses online shopping and ordering, but some products require a different packing material, and many times, shipping products can be wasteful. TemperPack aims to solve both issues with its ClimaCell liners, which you might recognize if you have ever ordered a meal subscription kit. Brian Powers, co-founder and Chief Growth Officer at TemperPack, joins Closing Bell to discuss TemperPack's ClimaCell liners, the company's sustainability mission, its corporate customer base, and more.
Bees are responsible for the bulk of fruit and vegetable pollination — and they're negatively being affected by climate change. Tech startup Beewise is offering a solution with artificial intelligence to create robotic, autonomous hives to help the vulnerable bee populations. Saar Safra, co-founder & CEO, joined Cheddar News to talk about the company's recent $80 million to help make this project possible. "Our solution is not only hardware," he said. "Its software and biology all in one device. That's the challenge, and that's what sets us apart."
Space tourism continues to be generating buzz after the most recent Blue Origin launch. Two of its passengers made history as the first married couple to travel to space. The couple, Marc Hagle, CEO at Tricor, and Sharon Hagle, CEO at Spacekids Global, joined Cheddar News fresh off of their trip to talk about their experience and future space travel plans. "If there is a Santa Claus, we’ll have the opportunity to fly with Virgin Galactic, and maybe we'll have the opportunity to fly with SpaceX," said Marc Hagle, followed by Sharon explaining they had already signed up with Virgin Galactic about 15 years ago.
The metaverse may be the next big thing in the music world. Cheddar News’ Michelle Castillo sat down with Jon Vlassopulos, VP and head of music at Roblox, to discuss virtual concerts and more.
The head of Russia’s space program says the future of the ISS hangs in the balance after the U.S., EU, and Canadian space agencies missed a deadline to meet Russian demands for lifting sanctions on Russian enterprises and hardware.
Catching you up on what you need to know on April 4, 2022, with reports of Russian war crimes in Ukraine, a weekend shooting in Sacramento killing six and injuring 12, Mexico ending its gas subsidization for U.S. drivers, and the University of South Carolina winning the women's NCAA basketball championship, and more.
Peter Zalzal, associate vice president for clean air strategies at the Environmental Defense Fund, a nonprofit environmental advocacy group, joined Cheddar to discuss the Biden Administration's unveiling of stricter fuel-efficiency standards for new automobiles. "The administration estimated that these rules will reduce about 2.5 billion tons of climate pollution by 2050, and using less fuel also means that we have to go to the gas pump less often. And so it means we save money, thousands of dollars in avoided fuel costs each year for consumers," he noted.
A 60-year-old man allegedly had himself vaccinated against COVID-19 dozens of times in Germany in order to sell forged vaccination cards with real vaccine batch numbers.
Between Bells EP Conor White recaps some of the biggest stories of the week, while Baker Machado and Hena Doba test their knowledge, and maybe learn a thing or two. It's This Week in Trivia!
